BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mortezaee K, Najafi M. Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives. Crit Rev Oncol Hematol 2021;157:103180. [PMID: 33264717 DOI: 10.1016/j.critrevonc.2020.103180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Hu W, Pei Y, Ning R, Li P, Zhang Z, Hong Z, Bao C, Guo X, Sun Y, Zhang Q. Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer. J Cancer Res Clin Oncol 2022. [PMID: 36138265 DOI: 10.1007/s00432-022-04194-9] [Reference Citation Analysis]
2 Shahverdi M, Masoumi J, Ghorbaninezhad F, Shajari N, Hajizadeh F, Hassanian H, Alizadeh N, Jafarlou M, Baradaran B. The modulatory role of dendritic cell-T cell cross-talk in breast cancer: Challenges and prospects. Adv Med Sci 2022;67:353-63. [PMID: 36116207 DOI: 10.1016/j.advms.2022.09.001] [Reference Citation Analysis]
3 Chen R, Zhai R, Wang C, Liang S, Wang J, Liu Z, Li W. Compound Capecitabine Colon-Targeted Microparticle Prepared by Coaxial Electrospray for Treatment of Colon Tumors. Molecules 2022;27:5690. [PMID: 36080457 DOI: 10.3390/molecules27175690] [Reference Citation Analysis]
4 Peltek OO, Ageev EI, Talianov PM, Mikushina AD, Epifanovskaya OS, Dubavik A, Veiko VP, Lepik K, Zuev DA, Timin AS, Zyuzin MV. Fluorescence-based thermometry for precise estimation of nanoparticle laser-induced heating in cancerous cells at nanoscale. Nanophotonics 2022;0. [DOI: 10.1515/nanoph-2022-0314] [Reference Citation Analysis]
5 Ponziani FR, Santopaolo F, Posa A, Pompili M, Tanzilli A, Maestri M, Pallozzi M, Ibba F, Manfredi R, Gasbarrini A, Iezzi R. SIRT in 2025. Cardiovasc Intervent Radiol 2022. [PMID: 35941244 DOI: 10.1007/s00270-022-03228-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu P, Ye M, Wu Y, Wu L, Lan K, Wu Z. Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes. Cancer Medicine. [DOI: 10.1002/cam4.5085] [Reference Citation Analysis]
7 Panpan T, Yuchen D, Xianyong S, Meng L, Ruijuan H, Ranran D, Pengyan Z, Mingxi L, Rongrong X. Cardiac Remodelling Following Cancer Therapy: A Review. Cardiovasc Toxicol 2022. [PMID: 35877038 DOI: 10.1007/s12012-022-09762-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhao S, Tang Y, Wang R, Najafi M. Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis 2022. [PMID: 35849264 DOI: 10.1007/s10495-022-01750-z] [Reference Citation Analysis]
9 Mortezaee K, Majidpoor J. Dysregulated metabolism: A friend-to-foe skewer of macrophages. International Reviews of Immunology. [DOI: 10.1080/08830185.2022.2095374] [Reference Citation Analysis]
10 Wu XY, Xu WW, Huan XK, Wu GN, Li G, Zhou YH, Najafi M. Mechanisms of cancer cell killing by metformin: a review on different cell death pathways. Mol Cell Biochem 2022. [PMID: 35771397 DOI: 10.1007/s11010-022-04502-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mortezaee K, Majidpoor J. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. Med Oncol 2022;39:131. [PMID: 35716327 DOI: 10.1007/s12032-022-01735-7] [Reference Citation Analysis]
12 Moslehi M, Moazamiyanfar R, Dakkali MS, Rezaei S, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, Khodamoradi E, Taeb S, Najafi M. Modulation of the immune system by melatonin; implications for cancer therapy. Int Immunopharmacol 2022;108:108890. [PMID: 35623297 DOI: 10.1016/j.intimp.2022.108890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Entezari M, Sadrkhanloo M, Rashidi M, Asnaf SE, Taheriazam A, Hashemi M, Ashrafizadeh M, Zarrabi A, Rabiee N, Hushmandi K, Mirzaei S, Sethi G. Non-coding RNAs and macrophage interaction in tumor progression. Crit Rev Oncol Hematol 2022;:103680. [PMID: 35405273 DOI: 10.1016/j.critrevonc.2022.103680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
14 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Huang J, Chang Z, Lu Q, Chen X, Najafi M. Nobiletin as an inducer of programmed cell death in cancer: a review. Apoptosis 2022. [PMID: 35312885 DOI: 10.1007/s10495-022-01721-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Mortezaee K, Majidpoor J. Checkpoint inhibitor/interleukin-based combination therapy of cancer. Cancer Med 2022. [PMID: 35301813 DOI: 10.1002/cam4.4659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Yin T, Wang P, Yu J, Teng F. Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma. Int Immunopharmacol 2022;106:108623. [PMID: 35203044 DOI: 10.1016/j.intimp.2022.108623] [Reference Citation Analysis]
18 Yu DL, Lou ZP, Ma FY, Najafi M. The interactions of paclitaxel with tumour microenvironment. Int Immunopharmacol 2022;105:108555. [PMID: 35121223 DOI: 10.1016/j.intimp.2022.108555] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
19 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
20 Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14:156. [PMID: 34579759 DOI: 10.1186/s13045-021-01164-5] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
21 Yu C, Yang B, Najafi M. Targeting of cancer cell death mechanisms by curcumin: Implications to cancer therapy. Basic Clin Pharmacol Toxicol 2021. [PMID: 34473898 DOI: 10.1111/bcpt.13648] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
22 Fu X, He Y, Li M, Huang Z, Najafi M. Targeting of the tumor microenvironment by curcumin. Biofactors 2021. [PMID: 34375483 DOI: 10.1002/biof.1776] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
23 Shi X, Liu Y, Cheng S, Hu H, Zhang J, Wei M, Zhao L, Xin S. Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma. Front Oncol 2021;11:651622. [PMID: 34367952 DOI: 10.3389/fonc.2021.651622] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 Mu Q, Najafi M. Modulation of the tumor microenvironment (TME) by melatonin. Eur J Pharmacol 2021;907:174365. [PMID: 34302814 DOI: 10.1016/j.ejphar.2021.174365] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
25 Kong WY, Ngai SC, Goh BH, Lee LH, Htar TT, Chuah LH. Is Curcumin the Answer to Future Chemotherapy Cocktail? Molecules 2021;26:4329. [PMID: 34299604 DOI: 10.3390/molecules26144329] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
26 Mortezaee K. Normalization in tumor ecosystem: Opportunities and challenges. Cell Biol Int 2021. [PMID: 34189798 DOI: 10.1002/cbin.11655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
27 Mu Q, Najafi M. Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells. Int Immunopharmacol 2021;98:107895. [PMID: 34171623 DOI: 10.1016/j.intimp.2021.107895] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
28 Chen L, Musa AE. Boosting immune system against cancer by resveratrol. Phytother Res 2021. [PMID: 34101276 DOI: 10.1002/ptr.7189] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
29 Fu X, Tang J, Wen P, Huang Z, Najafi M. Redox interactions-induced cardiac toxicity in cancer therapy. Arch Biochem Biophys 2021;708:108952. [PMID: 34097901 DOI: 10.1016/j.abb.2021.108952] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
30 Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. [PMID: 34004256 DOI: 10.1016/j.lfs.2021.119627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
31 Mortezaee K. Organ tropism in solid tumor metastasis: an updated review. Future Oncology 2021;17:1943-61. [DOI: 10.2217/fon-2020-1103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
32 Mortezaee K. Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. J Biochem Mol Toxicol 2021;35:e22708. [PMID: 33491255 DOI: 10.1002/jbt.22708] [Cited by in Crossref: 8] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]